About Exscientia
What Exscientia is building
Technologies used at Exscientia
AWS
SQL
PostgreSQL
Docker 
MongoDB
PythonFunding rounds
Total Funding
Last funding round type
Company type
Exscientia news and updates
Exscientia plc is developing cancer therapies
Exscientia and The University of Texas MD Anderson Cancer Center in the US have entered a strategic partnership to use artificial intelligence (AI) to develop new cancer therapies.
Nov 15, 2022 | pharmaceutical-technology.comExscientia plc hired Caroline Rowland as Chief People Officer on Sep 9th 22'.
Exscientia plc (Nasdaq: EXAI) today announced that Caroline Rowland has joined Exscientia as Chief People Officer.
Sep 8, 2022 | businesswirechina.comEvotec partners with Exscientia plc
4 To be clear, scenarios such as this are not science fiction -- the German biotechnology company Evotec recently partnered with UK-based Exscientia to use AI to identify a new anticancer drug candidate that is currently in Phase I clinical trials.
Aug 27, 2022 | patentdocs.orgSanofi partners with Exscientia plc
By India Today Web Desk : French drugmaker Sanofi SA will partner with British AI firm Exscientia Plc to develop up to 15 drug candidates across oncology and immunology, in a deal worth up to $5.2 billion in milestone payments, the two companies said on Friday.
Jan 7, 2022 | indiatoday.inRallybio partners with Exscientia
Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases.
Jan 1, 2022 | seekingalpha.comExscientia plc will go public on Sep 1st 22'.
In September of last year, we published a piece Comparing Four AI-Powered Drug Discovery Stocks, one of which – Exscientia – was preparing to IPO.
Jan 1, 2022 | nanalyze.comExscientia plc hired Michael Krams as Chief Quantitative Medicine Officer on Apr 5th 22'.
Exscientia Ltd. (Nasdaq: EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer.
Jan 1, 2022 | biospace.comExscientia plc received financing of $374M in disclosed funding on Jan 1st 12'.
Founded in 2012, Oxford’s own Exscientia raised $374.4 million in disclosed funding from a slew of investors including names like Softbank, BlackRock, Celgene, Bristol Myers Squibb, and Sir William of Gates.
Jan 1, 2021 | nanalyze.comBlackRock Inc invested into Exscientia plc in $30M on Mar 4th 21'.
Exscientia, leading AI drug discovery company, today announced that it completed its $100 million Series C financing round, with a further $30 million investment from Blackrock.
Jan 1, 2021 | hitconsultant.netExscientia plc went public on Oct 8th 21'.
Frontier IP Group PLC ( AIM:FIPP ) shares moved higher on Friday as the company highlighted the pricing of the initial public offering of Exscientia PLC, one of its portfolio companies.
Jan 1, 2021 | proactiveinvestors.co.ukExscientia plc receives financing of $525M
The Series C was ultimately expanded this past March when BlackRock pushed its total to $100 million, and Exscientia quickly raised another $525 million in late April — a raise that included a $252 Series D round, plus a $300 million equity investment by SoftBank.
Jan 1, 2021 | endpts.comExscientia plc hires Garry Pairaudeau as chief technology officer
Drug discovery firm Exscientia has beefed up its leadership team with the appointment of former AstraZeneca scientist Dr Garry Pairaudeau as its chief technology officer.
Jan 1, 2020 | pharmaphorum.comExscientia plc hires David Nicholson as chair of board of directors
Artificial intelligence-powered drugmaker Exscientia welcomed David Nicholson, PhD, as chair of its board of directors.
Jan 1, 2020 | beckershospitalreview.comExscientia plc hires David Hallett as Chief Operating Officer and head of drug discovery
Exscientia appoints Dr. David Hallett as Chief Operating Officer AI drug discovery company Exscientia has appointed Dr. David Hallett as its new Chief Operating Officer and head of drug discovery.
Jan 1, 2020 | information-age.comEgorov leaves Exscientia plc as CFO and Board member
Mr. Egorov joins Vaccitech from Exscientia, a global leader in AI drug discovery, where he was CFO and Board member.
Jan 1, 2020 | vaccitech.co.ukExscientia plc received financing of $4.2M in grant on Sep 8th 20'.
In a recent development, Exscientia announced that it has received $4.2M (nearly €3.44M) grant from Bill & Melinda Gates Foundation.
Jan 1, 2020 | siliconcanals.comExscientia plc received financing of $60M in Series C financing round on May 26th 20'.
(Sharecast News) - Intellectual property company Frontier IP said on Tuesday that its portfolio company, AI-driven drug discovery firm Exscientia, has raised $60m (£49.1m) through a series C financing round.
Jan 1, 2020 | lse.co.ukNovo Holdings invests into Exscientia plc in $60M
Novo Holdings leads the current US$60m Series C round of ExScientia Ltd, the world-leading artificial intelligence (AI)-driven drug discovery company.
Jan 1, 2020 | european-biotechnology.comBayer group partnered with Exscientia plc on Jan 1st 20'.
Bayer (ETR:BAYN) announced that it is entering into a collaboration agreement with artificial intelligence drug discovery company Exscientia to identify and optimize novel lead structures for potential drug candidates in treating cardiovascular and oncological diseases.
Jan 1, 2020 | massdevice.comExscientia plc partnered with Diamond Light Source Ltd on Mar 1st 20'.
Exscientia, the leading artificial intelligence (AI) driven drug discovery company, today announced a joint initiative with Diamond Light Source, the UK’s national synchrotron facility and Calibr, a division of Scripps Research (USA), to progress compounds that could rapidly become viable drugs for the rapid treatment of COVID-19.
Jan 1, 2020 | frontierip.co.ukExscientia plc partners with SRI International, Inc.
Banquet Buffet Frontier IP Group 69.5p £35.22m (AIM:FIPP) The Specialist in commercialising intellectual property, notes that portfolio company Exscientia, a world leader in AI-driven drug discovery, has entered into a collaboration with US research centre SRI International to expedite discovery of selective molecules for a high value oncology target.
Jan 1, 2020 | proactiveinvestors.co.ukExscientia plc partnered with Sumitomo Pharma on Jan 1st 19'.
The new compound, which has been designed to treat patients with obsessive-compulsive disorder, was developed by Oxford-based AI start-up Exscientia in collaboration with the Japanese pharmaceutical firm Sumitomo Dainippon Pharma.
Jan 1, 2020 | ft.comExscientia plc hires Andrew Douglas as Director of Data Engineering
Following a highly successful year and several drug discovery milestones using its flagship AI platform, Exscientia is pleased to welcome Andrew Douglas as the new Director of Data Engineering.
Jan 1, 2019 | prnewswire.comExscientia plc received financing of $26M in Series B financing round on Jan 1st 19'.
At the start of this year, the Oxford-based Exscientia secured a $26 million Series B investment to expand its capabilities, develop its platform and build its proprietary drug pipeline.
Jan 1, 2019 | contractpharma.comExscientia plc receives financing of $60M in Series C financing round
University of Dundee spin-out Exscientia has raised $60 million through a Series C financing round to back its work on AI-driven drug development.
Jan 1, 2019 | insider.co.ukCelgene Corp. invested into Exscientia plc in $26M on Jan 1st 19'.
In January, Exscientia announced that it had raised US$26 million in a Series B financing round from new investors Celgene Corporation and GT Healthcare Capital Partners, as well as existing investor Evotec AG.
Jan 1, 2019 | scotsman.comCelgene Corp. partners with Exscientia plc
Celgene has signed a deal with Artificial Intelligence specialists Exscientia to help accelerate its drug discovery in three therapeutic areas.
Jan 1, 2019 | pmlive.comExscientia plc partners with Genzyme GmbH
Exscientia had earlier teamed up with pharma majors Roche, GlaxoSmithKline and Sanofi.
Jan 1, 2019 | indiatimes.comExscientia plc launches artificial intelligence platform
Exscientia has developed an artificial intelligence platform to boost drug discovery in pharma and biotech.
Jan 1, 2019 | labiotech.euExscientia plc is developing small molecule drugs
Under the deal Exscientia will develop small molecule drugs for up to 10 disease targets nominated by GSK, and is worth up to £33 million if all these milestones are met.
Jan 1, 2019 | pharmaphorum.comExscientia plc went public on May 1st 20'.
The Daily Telegraph understands that Dundee University spin-off Exscientia, which uses AI to help find blockbuster pharma drugs, is considering an initial public offering, and will be ready to float by next May.
Jan 1, 2019 | telegraph.co.ukExscientia plc hires Iva Navratilova as chief biophysicist
Kinetic's founder and Chief Scientific Officer, Dr Iva Navratilova, will join Exscientia as its Chief Biophysicist.
Jan 1, 2018 | prnewswire.comExscientia plc acquired Kinetic Discovery Ltd for $3.32M on Jan 1st 18'.
Oxford-based Exscientia said it has acquired the privately owned biophysics specialist, Kinetic Discovery.
Jan 1, 2018 | pharmaphorum.comExscientia plc hires Mario Polywka as Board of Directors
I’m also delighted that Dr Mario Polywka, Chief Operating Officer of Evotec, will join Exscientia’s Board of Directors, allowing Exscientia to benefit from his strong operational expertise in growing successful biotech companies”.
Jan 1, 2017 | exscientia.co.ukExscientia plc hired Alex Snow as Deputy Chairman on Jan 1st 17'.
Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce the appointment of Mr Alex Snow to its Board of Directors as Deputy Chairman.
Jan 1, 2017 | exscientia.co.ukEvotec AG invested into Exscientia plc in $16.7M on Sep 28th 17'.
Exscientia, a Scotland-based drug developer spun out from University of Dundee, raised €15m ($17.7m) in funding yesterday from drug discovery company Evotec.
Jan 1, 2017 | globaluniversityventuring.comSanofi SA partners with Exscientia plc
Sanofi has teamed up with Exscientia to discover and develop bispecific small molecules that treat diabetes and its comorbidities.
Jan 1, 2017 | fiercebiotech.comSunovion Pharmaceuticals Inc. partners with Exscientia plc
Companies such as Celgene, GSK, Sanofi, and Sunovion have partnered with Exscientia to solve this problem.
Jan 1, 2017 | thermofisher.com